Alpine Immune Sciences (NASDAQ:ALPN) Upgraded by Zacks Investment Research to “Buy”


Share on StockTwits

Zacks Investment Research upgraded shares of Alpine Immune Sciences (NASDAQ:ALPN) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $15.00 price objective on the biotechnology company’s stock.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Separately, HC Wainwright started coverage on Alpine Immune Sciences in a report on Monday, December 21st. They set a buy rating and a $21.00 price target for the company. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and an average target price of $18.67.

Alpine Immune Sciences stock traded up $0.54 on Wednesday, hitting $13.77. 943 shares of the stock traded hands, compared to its average volume of 105,589. The company has a current ratio of 3.98, a quick ratio of 3.98 and a debt-to-equity ratio of 0.13. The firm has a market cap of $327.77 million, a P/E ratio of -9.19 and a beta of 1.72. The business’s fifty day simple moving average is $12.64 and its 200 day simple moving average is $9.77. Alpine Immune Sciences has a 1 year low of $2.05 and a 1 year high of $16.37.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings data on Tuesday, November 17th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.05). The firm had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $4.80 million. Alpine Immune Sciences had a negative net margin of 606.16% and a negative return on equity of 80.38%. As a group, analysts predict that Alpine Immune Sciences will post -1.4 earnings per share for the current year.

In other Alpine Immune Sciences news, Director Robert E. Conway acquired 10,000 shares of Alpine Immune Sciences stock in a transaction that occurred on Thursday, November 19th. The stock was bought at an average cost of $8.03 per share, for a total transaction of $80,300.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 600,000 shares of Alpine Immune Sciences stock in a transaction dated Monday, December 28th. The stock was sold at an average price of $14.25, for a total value of $8,550,000.00. The disclosure for this sale can be found here. 76.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALPN. EcoR1 Capital LLC bought a new stake in Alpine Immune Sciences in the 3rd quarter worth about $6,516,000. Samsara BioCapital LLC bought a new stake in Alpine Immune Sciences in the 3rd quarter worth about $4,344,000. Sphera Funds Management LTD. bought a new stake in Alpine Immune Sciences in the 3rd quarter worth about $1,743,000. Finally, Leonard Rickey Investment Advisors P.L.L.C. increased its holdings in Alpine Immune Sciences by 70.1% in the 3rd quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 17,013 shares of the biotechnology company’s stock worth $150,000 after buying an additional 7,013 shares in the last quarter. Institutional investors own 52.86% of the company’s stock.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Further Reading: What is Cost of Debt?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.